Testimonials

Background stories of how others approached and experienced their European Horizon funding trajectory.

STARGATE - Sustainable Aviation

image of STARGATE - Sustainable Aviation

Published on | 2 years ago

Programmes Climate, Energy, Mobility Transport Green Deal

The Stargate project obtained funding under the special Green Deal call of Horizon 2020, more in particular under the topic of “green ports and airports”.  It received the maximum score of the evaluators and was selected out of more than 40 projects. Stargate’s purpose is to prove that sustainable aviation is possible and happening. It focuses on the further decarbonization of the aviation industry, the improvement of local environmental quality and the stimulation of the modal split. Together with a consortium of 21 European partners with a diverse and rich expertise (airports, community partners, knowledge institutions, consultants, local governments, …), Brussels Airports takes the lead as lighthouse airport to develop and implement innovative solutions. Results that prove successful can be deployed at the fellow airports (Toulouse, Budapest, Athens). Over the course of the coming five years, the consortium will exchange knowledge to investigate and realize more than 30 concrete projects.

Read the full article for details 
Other available testimonials

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.